phenelzine
Trade name: nardil
Approved
Jun 9, 1961
Phenelzine is an irreversible non-selective inhibitor of monoamine oxidase. Although the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron. Phenelzine is used for the treatment of major depressive disorder. Has also been used with some success in the management of bulimia nervosa. — NCATS
Clinical trial activity
9 trials · 12 clinical orgs · 2 marketing orgs
Earliest trial started Jul 12, 2010 (NCT01253642)
Timeline
1960s
- Jun 9, 1961
Parke-Davis — Earliest FDA Approval
- Jun 9, 1961
Parke-Davis — NDA Organization
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
- Dec 8, 2010
Novel Anti-Infective Technologies, LLC — Marketing Organization
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Monoamine oxidaseINHIBITOR
Monoamine oxidase inhibitor
Approval history
- approvedJun 9, 1961
Chemistry & pharmacology
SMILES
NNCCc1ccccc1- Mol. weight
- 136.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1089 ↗
- WikipediaPhenelzine ↗
- NCATSO408N561GF ↗
- ChEMBLCHEMBL1200895 ↗
Also known as
- 1-hydrazino-2-phenylethane
- 2-phenylethylhydrazine
- fenelzina
- fenelzina
- nardil
- nardil
- nardil
- nardil
- phenalzine
- phenelzin
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phenelzine
- phénelzine
- phénelzine
- phenelzine sulfate
- phenelzine sulfate
- phenelzine sulfate
- phenelzine sulfate
- phenelzine sulfate
- phenelzinum
- phenelzinum
- phenethylhydrazine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06580041 | Phase 4 | Nov 12, 2024 | University of California, San Francisco |
| NCT04978298 | Phase 1 | Jul 19, 2021 | Celgene |
| NCT03979820 | Phase 1 | Jul 8, 2019 | Boehringer Ingelheim |
| NCT03694119 | Phase 1 | Jul 24, 2018 | Celgene |
| NCT03505528 | Phase 1 | Aug 17, 2017 | Australian National University, EpiAxis Therapeutics, Government of Australia, Southern Medical Day Care Centre |
| NCT02269540 | Early Phase 1 (Phase 1) | Oct 1, 2014 | University of Toronto |
| NCT02217709 | Phase 2 | Sep 8, 2014 | National Cancer Institute (NCI), University of Southern California |
| NCT02153281 | N/A | Jun 30, 2014 | University of Toronto |
| NCT01253642 | Phase 2 | Jul 12, 2010 | National Cancer Institute (NCI), Oregon Health and Science University, The Wayne D. Kuni and Joan E. Kuni Foundation |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 2 | 2 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2010 |
| University of Toronto | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Australian National University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2019 |
| EpiAxis Therapeutics | For profit | 1 | 1 | 1 | 2017 |
| Government of Australia | Government | 1 | 0 | 1 | 2017 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Southern Medical Day Care Centre | Academic/Hospital | 1 | 0 | 1 | 2017 |
| The Wayne D. Kuni and Joan E. Kuni Foundation | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2014 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Novel Anti-Infective Technologies, LLC | For profit | MKTG | Dec 8, 2010 |
| Parke-Davis | For profit | NDA | Jun 9, 1961 |